Adherence with urate-lowering therapies for the treatment of gout

Table 3 Adjusted logistic regression model for non-adherence (medication possession ratio (MPR) < 0.80)*

Variable†	Adjusted odds ratio (95% confidence interval)
Sociodemographic:
Gender, female	1.03 (0.88 to 1.19)
Age
<45	2.43 (1.86 to 3.18)
45 to 49	1.45 (1.08 to 1.93)
50 to 54	1.09 (0.86 to 1.39)
55 to 59	0.78 (0.61 to 0.99)
60 to 64	0.75 (0.59 to 0.96)
65 to 69	0.84 (0.67 to 1.04)
70 to 74	0.83 (0.67 to 1.02)
75 +	1.00
Health status:
Charlson comorbidity score
0	1.46 (1.20 to 1.77)
1	1.21 (0.98 to 1.51)
2	1.20 (0.94 to 1.53)
3 or more	1.00
Gout care:
Number of provider visits for gout prior to ULD initiation
0	1.28 (1.05 to 1.55)
1	1.09 (0.92 to 1.30)
2	1.00 (0.83 to 1.21)
3 or more	1.00
Use of acute gout meds 1 to 12 months prior to urate-lowering drug initiation
NSAIDs	1.15 (1.00 to 1.31)

*A backward elimination method was used retaining all variables considered to be potentially important. Variables with P values < 0.10 remained in the final models. The Hosmer-Lemeshow goodness of fit had a P value of 0.70; †model after controlling for health plan.
NSAID, non-steroidal anti-inflammatory drug; ULD, urate-lowering drug.

ISSN: 1478-6362